Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. co-Chief Executive Officer Helmy Eltoukhy reported routine equity compensation activity involving restricted stock units and related common stock. On March 31 and April 1, 2026, multiple restricted stock unit awards converted into an aggregate of tens of thousands of shares of common stock at a $0.00 exercise price.
To cover associated tax obligations upon these vesting events, a total of 18,515 shares of common stock were retained by the company at prices of $92.37 and $91.15 per share, characterized as tax-withholding dispositions rather than open-market sales. Following these transactions, a revocable trust associated with Eltoukhy held 2,112,919 shares of common stock, and he directly held 68,011 restricted stock units. The filing reflects compensation-related vesting and tax withholding, not discretionary market trading.
Guardant Health director Steve E. Krognes acquired 155 shares of Common Stock through the vesting and exercise of Restricted Stock Units. The transaction occurred on March 31, 2026 at an exercise price of $0.00 per share, reflecting a routine equity-compensation event rather than an open-market purchase.
The 155 Restricted Stock Units converted into 155 shares of Common Stock, increasing his direct Common Stock holdings to 19,208 shares following the transaction. He also continues to hold 463 Restricted Stock Units after this vesting. The underlying award was originally granted on August 9, 2022 and vests over four years, with 25% vesting on June 30, 2023 and the remaining 75% vesting in substantially equal monthly installments over the subsequent three years.
Guardant Health Inc Amendment No. 4 to a Schedule 13G/A reports that The Vanguard Group holds 0 shares and 0% of Guardant Health common stock following an internal realignment. The filing cites SEC Release No. 34-39538 and states Vanguard subsidiaries will report separately.
Guardant Health director Roberto Mignone reported the vesting and settlement of 264 restricted stock units into an equal number of common shares at a price of $0.00 per share, reflecting a routine equity compensation event rather than an open-market trade.
After this derivative exercise, Mignone directly holds 4,487 shares of common stock and 8,184 restricted stock units. The vested RSUs come from an award granted on November 8, 2024 that vests 25% on the one-year anniversary of October 21, 2024, with the remaining 75% vesting monthly over the following three years.
Guardant Health director Tariq Musa reported an open-market sale of 348 shares of Guardant Health common stock on March 18, 2026, at an average price of $88.09 per share. After this transaction, he directly holds 8,394 shares of the company’s stock.
Guardant Health director Manuel Hidalgo Medina exercised restricted stock units into common shares as part of his equity compensation. On March 17, 2026, 232 restricted stock units converted into 232 shares of common stock at a stated price of $0.00 per share, raising his direct common stock holdings to 1,425 shares. The award originated from a grant on July 17, 2024 that vests over four years, with 25% vesting on the one-year anniversary and the remaining 75% vesting monthly over the following three years.
Guardant Health filing: a Form 144 notice lists proposed dispositions of Common Stock tied to restricted stock lapses. The filing names Charles Schwab & Co., Inc. as broker and shows scheduled events on 01/15/2026 and 02/15/2026 for 250 and 98 shares respectively. The entries are labeled "Restricted Stock Lapse" and "Equity Compensation." No securities sold during the past three months are reported in the excerpt.
Guardant Health Co-CEO AmirAli Talasaz reported compensation-related equity activity and trust-related share movements. On March 17, 2026, he received awards of 11,268 and 101,409 restricted stock units that vest over quarterly and multi-year schedules. Earlier, on January 1 and March 13, 2026, performance-based and time-based RSUs covering 38,283 and 26,961 shares were exercised into common stock, with 19,402 and 13,664 shares withheld by the company to cover tax obligations. In connection with these events, 13,209 common shares were transferred from direct ownership into the Talasaz and Eskandari 2017 Family Trust, which held 2,128,489 shares after the March 13, 2026 transactions.
Guardant Health Co-CEO Helmy Eltoukhy reported compensation-related equity activity and trust transfers, not open‑market trading. On March 17, 2026, he received two new restricted stock unit awards covering 11,268 and 101,409 shares of common stock, with multi-year vesting schedules.
On January 1, 2026 and March 13, 2026, performance-based and time-based RSUs were exercised into a total of 65,244 shares of common stock. In connection with these vestings, the company withheld 19,402 and 13,664 shares to cover tax obligations, which were not market sales.
The filing also records a transfer of 13,209 shares from direct ownership to the Helmy A. Eltoukhy Revocable Trust, after which the trust held 2,094,904 shares. Overall, the transactions increase his equity-based compensation and shift holdings into a revocable trust while maintaining a substantial indirect position.
Guardant Health director Tariq Musa exercised restricted stock units into common shares as part of a scheduled vesting. On March 15, 2026, 249 restricted stock units converted into 249 shares of common stock at a stated price of $0.0000 per share.
Following the transactions, he held 8,742 shares of common stock directly and 2,999 restricted stock units. The underlying restricted stock unit award was granted on March 6, 2023 and vests over four years, with 25% vesting on the one-year anniversary of March 15, 2023 and the remaining 75% vesting monthly over the subsequent three years.